Search results
ASCO24: Novartis’ Scemblix outperforms standard of care in CML
Pharmaceutical Technology· 5 days agoThe results from the open-label Phase III ASC4FIRST study (NCT04971226) were released in a...
The results from the open-label Phase III ASC4FIRST study (NCT04971226) were released in a...